Viewing Study NCT04476459

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 2:48 PM
Ignite Modification Date: 2026-01-29 @ 9:18 PM
Study NCT ID: NCT04476459
Status: UNKNOWN
Last Update Posted: 2021-03-15
First Post: 2020-07-15
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL
Sponsor: Huiqiang Huang
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Diffuse Large B Cell Lymphoma View
None High-grade B-cell Lymphoma View
None Follicular Lymphoma Grade IIIb View
None Transformed Lymphoma View
None EBV-Positive DLBCL, Nos View
None ALK-Positive Anaplastic Large Cell Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None DLBCL View
None relapsed View
None refractory View